68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients
Background To evaluate the role of 68 Gallium prostate-specific membrane antigen-positron emission tomography/computed tomography ( 68 Ga-PSMA-11 PET/CT) derived quantitative volumetric tumor parameters in comparison with fully diagnostic conventional CT and serum-PSA levels for classification and e...
Gespeichert in:
| Veröffentlicht in: | Annals of nuclear medicine 2019-10, Vol.33 (10), p.766-775 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 775 |
|---|---|
| container_issue | 10 |
| container_start_page | 766 |
| container_title | Annals of nuclear medicine |
| container_volume | 33 |
| creator | Schmidkonz, Christian Cordes, Michael Goetz, Theresa Ida Prante, Olaf Kuwert, Torsten Ritt, Philipp Uder, Michael Wullich, Bernd Goebell, Peter Bäuerle, Tobias |
| description | Background
To evaluate the role of
68
Gallium prostate-specific membrane antigen-positron emission tomography/computed tomography (
68
Ga-PSMA-11 PET/CT) derived quantitative volumetric tumor parameters in comparison with fully diagnostic conventional CT and serum-PSA levels for classification and evaluation of therapeutic response of bone metastases in patients with metastasized prostate cancer (PC).
Methods
A total of 177 men with biochemical recurrence of prostate cancer suffering from bone metastases underwent PET/CT with [
68
Ga] Ga-PSMA-HBED-CC (
68
Ga-PSMA-11). To calculate
68
Ga-PSMA-11 PET quantitative volumetric tumor parameters including whole-body total-lesion PSMA (TL-PSMA), whole-body PSMA-tumor volume (PSMA-TV), as well as the established maximum standard uptake values (SUVmax) and mean standard uptake values (SUVmean), all 443
68
Ga-PSMA-11-positive bone lesions in the field of view were assessed quantitatively. Quantitative volumetric tumor parameters were correlated with CT-derived volume and bone density measurements of metastatic bone lesions, serum prostate-specific antigen (PSA) levels, and Gleason Scores. In the 20 patients suffering from bone metastases who underwent
68
Ga-PSMA-11 PET/CT before and after therapy, CT-derived volume and bone density measurements of metastatic lesions were compared to biochemical response determined by serum-PSA levels.
Results
In 177 patients, a total of 443
68
Ga-PSMA-11 PET-positive bone lesions were detected. Of these, 50 lesions (11%) were only detectable on PET but not on conventional CT. PET-positive/CT-negative bone metastases demonstrated a significantly lower PSMA uptake compared to PET-positive/CT-positive bone lesions (
p
0.05) before and after therapy, while a highly significant correlation was observed for changes of PSMA-TV, TL-PSMA, and serum-PSA levels (
p
|
| doi_str_mv | 10.1007/s12149-019-01387-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2263323253</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2263323253</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-36299b37958a50ce7a54cb47d86fc5971b54c8ec66263f4426b54854d922381a3</originalsourceid><addsrcrecordid>eNp9kd2K1TAUhYMoznH0BbyQgDfexMlf2-RyOIyjMOKAx-uSprvaoU07-TngQ_mO7mNHBS-EhLB2vr12wiLkpeBvBefNRRJSaMu4OG1lGsYfkZ0wtWa1Vuox2XErNGuEac7Is5TuOJemMvIpOVNCIa_EjvyozbVjt58_XjIh6O3V4WJ_oD3E8Qg9vS8u5DG7jIoel6nMkOPoaS7zEunqosMCxEQHlH5yKY3D6BFfAnWhp3B0U9nkMtD8DaJboWR0iJDWJSQ41bslAEUjl3BBomOga1xQZKDeBQ-nUXmEkNNz8mRwU4IXD-c5-fLu6rB_z24-XX_YX94wr6zNTNXS2k41tjKu4h4aV2nf6aY39eAr24gOtQFf17JWg9ayxoKpdG-lVEY4dU7ebL74kPsCKbfzmDxMkwuwlNRK7FNSyUoh-vof9G4pMeDrkLJWN5YrjZTcKI8_SxGGdo3j7OL3VvD2FGa7hdlimO2vMFuOTa8erEs3Q_-n5Xd6CKgNSHgVvkL8O_s_tj8Bk52rsQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2299479034</pqid></control><display><type>article</type><title>68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Schmidkonz, Christian ; Cordes, Michael ; Goetz, Theresa Ida ; Prante, Olaf ; Kuwert, Torsten ; Ritt, Philipp ; Uder, Michael ; Wullich, Bernd ; Goebell, Peter ; Bäuerle, Tobias</creator><creatorcontrib>Schmidkonz, Christian ; Cordes, Michael ; Goetz, Theresa Ida ; Prante, Olaf ; Kuwert, Torsten ; Ritt, Philipp ; Uder, Michael ; Wullich, Bernd ; Goebell, Peter ; Bäuerle, Tobias</creatorcontrib><description>Background
To evaluate the role of
68
Gallium prostate-specific membrane antigen-positron emission tomography/computed tomography (
68
Ga-PSMA-11 PET/CT) derived quantitative volumetric tumor parameters in comparison with fully diagnostic conventional CT and serum-PSA levels for classification and evaluation of therapeutic response of bone metastases in patients with metastasized prostate cancer (PC).
Methods
A total of 177 men with biochemical recurrence of prostate cancer suffering from bone metastases underwent PET/CT with [
68
Ga] Ga-PSMA-HBED-CC (
68
Ga-PSMA-11). To calculate
68
Ga-PSMA-11 PET quantitative volumetric tumor parameters including whole-body total-lesion PSMA (TL-PSMA), whole-body PSMA-tumor volume (PSMA-TV), as well as the established maximum standard uptake values (SUVmax) and mean standard uptake values (SUVmean), all 443
68
Ga-PSMA-11-positive bone lesions in the field of view were assessed quantitatively. Quantitative volumetric tumor parameters were correlated with CT-derived volume and bone density measurements of metastatic bone lesions, serum prostate-specific antigen (PSA) levels, and Gleason Scores. In the 20 patients suffering from bone metastases who underwent
68
Ga-PSMA-11 PET/CT before and after therapy, CT-derived volume and bone density measurements of metastatic lesions were compared to biochemical response determined by serum-PSA levels.
Results
In 177 patients, a total of 443
68
Ga-PSMA-11 PET-positive bone lesions were detected. Of these, 50 lesions (11%) were only detectable on PET but not on conventional CT. PET-positive/CT-negative bone metastases demonstrated a significantly lower PSMA uptake compared to PET-positive/CT-positive bone lesions (
p
< 0.05). SUVmax, SUVmean, PSMA-TV, and TL-PSMA of bone metastases were significantly higher (
p
< 0.05) in patients with Gleason Scores > 7 compared to those with Gleason Scores ≤ 7. In the linear regression analysis, an association was determined between SUVmean, Gleason Scores, lesion classification, and serum-PSA levels but not for CT-derived bone density measurements. No significant correlation could be found between changes of bone density and CT-derived volume measurements of metastatic bone lesions and changes of serum-PSA levels (
p
> 0.05) before and after therapy, while a highly significant correlation was observed for changes of PSMA-TV, TL-PSMA, and serum-PSA levels (
p
< 0.001).
Conclusion
Our results suggest that
68
Ga-PSMA-11 PET/CT might be a valuable tool for the detection and follow-up of bone metastases in patients with metastasized prostate cancer.
68
Ga-PSMA-11 PET-derived quantitative volumetric parameters demonstrated a highly significant correlation with changes of serum-PSA levels during the course of therapy. No such correlation could be determined for bone density measurements of metastatic bone lesions. Compared to the fully diagnostic CT scan, a significantly higher proportion of bone metastases was detected on
68
Ga-PSMA-11 PET.</description><identifier>ISSN: 0914-7187</identifier><identifier>EISSN: 1864-6433</identifier><identifier>DOI: 10.1007/s12149-019-01387-0</identifier><identifier>PMID: 31338731</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Aged ; Aged, 80 and over ; Antigens ; Bone cancer ; Bone density ; Bone lesions ; Bone Neoplasms - diagnostic imaging ; Bone Neoplasms - secondary ; Bone Neoplasms - therapy ; Classification ; Computed tomography ; Correlation analysis ; Diagnostic systems ; Edetic Acid - analogs & derivatives ; Emission analysis ; Evaluation ; Field of view ; Humans ; Imaging ; Lesions ; Male ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Middle Aged ; Neoplasm Grading ; Nuclear Medicine ; Oligopeptides ; Original Article ; Parameters ; Personal computers ; Positron emission ; Positron emission tomography ; Positron Emission Tomography Computed Tomography ; Prostate cancer ; Prostate-specific antigen ; Prostatic Neoplasms - metabolism ; Prostatic Neoplasms - pathology ; Radiology ; Recurrence ; Regression analysis ; Therapy ; Time Factors ; Tomography ; Treatment Outcome ; Tumors</subject><ispartof>Annals of nuclear medicine, 2019-10, Vol.33 (10), p.766-775</ispartof><rights>The Japanese Society of Nuclear Medicine 2019</rights><rights>Copyright Springer Nature B.V. 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-36299b37958a50ce7a54cb47d86fc5971b54c8ec66263f4426b54854d922381a3</citedby><cites>FETCH-LOGICAL-c399t-36299b37958a50ce7a54cb47d86fc5971b54c8ec66263f4426b54854d922381a3</cites><orcidid>0000-0002-1988-0058</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12149-019-01387-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12149-019-01387-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31338731$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schmidkonz, Christian</creatorcontrib><creatorcontrib>Cordes, Michael</creatorcontrib><creatorcontrib>Goetz, Theresa Ida</creatorcontrib><creatorcontrib>Prante, Olaf</creatorcontrib><creatorcontrib>Kuwert, Torsten</creatorcontrib><creatorcontrib>Ritt, Philipp</creatorcontrib><creatorcontrib>Uder, Michael</creatorcontrib><creatorcontrib>Wullich, Bernd</creatorcontrib><creatorcontrib>Goebell, Peter</creatorcontrib><creatorcontrib>Bäuerle, Tobias</creatorcontrib><title>68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients</title><title>Annals of nuclear medicine</title><addtitle>Ann Nucl Med</addtitle><addtitle>Ann Nucl Med</addtitle><description>Background
To evaluate the role of
68
Gallium prostate-specific membrane antigen-positron emission tomography/computed tomography (
68
Ga-PSMA-11 PET/CT) derived quantitative volumetric tumor parameters in comparison with fully diagnostic conventional CT and serum-PSA levels for classification and evaluation of therapeutic response of bone metastases in patients with metastasized prostate cancer (PC).
Methods
A total of 177 men with biochemical recurrence of prostate cancer suffering from bone metastases underwent PET/CT with [
68
Ga] Ga-PSMA-HBED-CC (
68
Ga-PSMA-11). To calculate
68
Ga-PSMA-11 PET quantitative volumetric tumor parameters including whole-body total-lesion PSMA (TL-PSMA), whole-body PSMA-tumor volume (PSMA-TV), as well as the established maximum standard uptake values (SUVmax) and mean standard uptake values (SUVmean), all 443
68
Ga-PSMA-11-positive bone lesions in the field of view were assessed quantitatively. Quantitative volumetric tumor parameters were correlated with CT-derived volume and bone density measurements of metastatic bone lesions, serum prostate-specific antigen (PSA) levels, and Gleason Scores. In the 20 patients suffering from bone metastases who underwent
68
Ga-PSMA-11 PET/CT before and after therapy, CT-derived volume and bone density measurements of metastatic lesions were compared to biochemical response determined by serum-PSA levels.
Results
In 177 patients, a total of 443
68
Ga-PSMA-11 PET-positive bone lesions were detected. Of these, 50 lesions (11%) were only detectable on PET but not on conventional CT. PET-positive/CT-negative bone metastases demonstrated a significantly lower PSMA uptake compared to PET-positive/CT-positive bone lesions (
p
< 0.05). SUVmax, SUVmean, PSMA-TV, and TL-PSMA of bone metastases were significantly higher (
p
< 0.05) in patients with Gleason Scores > 7 compared to those with Gleason Scores ≤ 7. In the linear regression analysis, an association was determined between SUVmean, Gleason Scores, lesion classification, and serum-PSA levels but not for CT-derived bone density measurements. No significant correlation could be found between changes of bone density and CT-derived volume measurements of metastatic bone lesions and changes of serum-PSA levels (
p
> 0.05) before and after therapy, while a highly significant correlation was observed for changes of PSMA-TV, TL-PSMA, and serum-PSA levels (
p
< 0.001).
Conclusion
Our results suggest that
68
Ga-PSMA-11 PET/CT might be a valuable tool for the detection and follow-up of bone metastases in patients with metastasized prostate cancer.
68
Ga-PSMA-11 PET-derived quantitative volumetric parameters demonstrated a highly significant correlation with changes of serum-PSA levels during the course of therapy. No such correlation could be determined for bone density measurements of metastatic bone lesions. Compared to the fully diagnostic CT scan, a significantly higher proportion of bone metastases was detected on
68
Ga-PSMA-11 PET.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antigens</subject><subject>Bone cancer</subject><subject>Bone density</subject><subject>Bone lesions</subject><subject>Bone Neoplasms - diagnostic imaging</subject><subject>Bone Neoplasms - secondary</subject><subject>Bone Neoplasms - therapy</subject><subject>Classification</subject><subject>Computed tomography</subject><subject>Correlation analysis</subject><subject>Diagnostic systems</subject><subject>Edetic Acid - analogs & derivatives</subject><subject>Emission analysis</subject><subject>Evaluation</subject><subject>Field of view</subject><subject>Humans</subject><subject>Imaging</subject><subject>Lesions</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Nuclear Medicine</subject><subject>Oligopeptides</subject><subject>Original Article</subject><subject>Parameters</subject><subject>Personal computers</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Prostate cancer</subject><subject>Prostate-specific antigen</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Radiology</subject><subject>Recurrence</subject><subject>Regression analysis</subject><subject>Therapy</subject><subject>Time Factors</subject><subject>Tomography</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0914-7187</issn><issn>1864-6433</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kd2K1TAUhYMoznH0BbyQgDfexMlf2-RyOIyjMOKAx-uSprvaoU07-TngQ_mO7mNHBS-EhLB2vr12wiLkpeBvBefNRRJSaMu4OG1lGsYfkZ0wtWa1Vuox2XErNGuEac7Is5TuOJemMvIpOVNCIa_EjvyozbVjt58_XjIh6O3V4WJ_oD3E8Qg9vS8u5DG7jIoel6nMkOPoaS7zEunqosMCxEQHlH5yKY3D6BFfAnWhp3B0U9nkMtD8DaJboWR0iJDWJSQ41bslAEUjl3BBomOga1xQZKDeBQ-nUXmEkNNz8mRwU4IXD-c5-fLu6rB_z24-XX_YX94wr6zNTNXS2k41tjKu4h4aV2nf6aY39eAr24gOtQFf17JWg9ayxoKpdG-lVEY4dU7ebL74kPsCKbfzmDxMkwuwlNRK7FNSyUoh-vof9G4pMeDrkLJWN5YrjZTcKI8_SxGGdo3j7OL3VvD2FGa7hdlimO2vMFuOTa8erEs3Q_-n5Xd6CKgNSHgVvkL8O_s_tj8Bk52rsQ</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Schmidkonz, Christian</creator><creator>Cordes, Michael</creator><creator>Goetz, Theresa Ida</creator><creator>Prante, Olaf</creator><creator>Kuwert, Torsten</creator><creator>Ritt, Philipp</creator><creator>Uder, Michael</creator><creator>Wullich, Bernd</creator><creator>Goebell, Peter</creator><creator>Bäuerle, Tobias</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1988-0058</orcidid></search><sort><creationdate>20191001</creationdate><title>68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients</title><author>Schmidkonz, Christian ; Cordes, Michael ; Goetz, Theresa Ida ; Prante, Olaf ; Kuwert, Torsten ; Ritt, Philipp ; Uder, Michael ; Wullich, Bernd ; Goebell, Peter ; Bäuerle, Tobias</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-36299b37958a50ce7a54cb47d86fc5971b54c8ec66263f4426b54854d922381a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antigens</topic><topic>Bone cancer</topic><topic>Bone density</topic><topic>Bone lesions</topic><topic>Bone Neoplasms - diagnostic imaging</topic><topic>Bone Neoplasms - secondary</topic><topic>Bone Neoplasms - therapy</topic><topic>Classification</topic><topic>Computed tomography</topic><topic>Correlation analysis</topic><topic>Diagnostic systems</topic><topic>Edetic Acid - analogs & derivatives</topic><topic>Emission analysis</topic><topic>Evaluation</topic><topic>Field of view</topic><topic>Humans</topic><topic>Imaging</topic><topic>Lesions</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Nuclear Medicine</topic><topic>Oligopeptides</topic><topic>Original Article</topic><topic>Parameters</topic><topic>Personal computers</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Prostate cancer</topic><topic>Prostate-specific antigen</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Radiology</topic><topic>Recurrence</topic><topic>Regression analysis</topic><topic>Therapy</topic><topic>Time Factors</topic><topic>Tomography</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schmidkonz, Christian</creatorcontrib><creatorcontrib>Cordes, Michael</creatorcontrib><creatorcontrib>Goetz, Theresa Ida</creatorcontrib><creatorcontrib>Prante, Olaf</creatorcontrib><creatorcontrib>Kuwert, Torsten</creatorcontrib><creatorcontrib>Ritt, Philipp</creatorcontrib><creatorcontrib>Uder, Michael</creatorcontrib><creatorcontrib>Wullich, Bernd</creatorcontrib><creatorcontrib>Goebell, Peter</creatorcontrib><creatorcontrib>Bäuerle, Tobias</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schmidkonz, Christian</au><au>Cordes, Michael</au><au>Goetz, Theresa Ida</au><au>Prante, Olaf</au><au>Kuwert, Torsten</au><au>Ritt, Philipp</au><au>Uder, Michael</au><au>Wullich, Bernd</au><au>Goebell, Peter</au><au>Bäuerle, Tobias</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients</atitle><jtitle>Annals of nuclear medicine</jtitle><stitle>Ann Nucl Med</stitle><addtitle>Ann Nucl Med</addtitle><date>2019-10-01</date><risdate>2019</risdate><volume>33</volume><issue>10</issue><spage>766</spage><epage>775</epage><pages>766-775</pages><issn>0914-7187</issn><eissn>1864-6433</eissn><abstract>Background
To evaluate the role of
68
Gallium prostate-specific membrane antigen-positron emission tomography/computed tomography (
68
Ga-PSMA-11 PET/CT) derived quantitative volumetric tumor parameters in comparison with fully diagnostic conventional CT and serum-PSA levels for classification and evaluation of therapeutic response of bone metastases in patients with metastasized prostate cancer (PC).
Methods
A total of 177 men with biochemical recurrence of prostate cancer suffering from bone metastases underwent PET/CT with [
68
Ga] Ga-PSMA-HBED-CC (
68
Ga-PSMA-11). To calculate
68
Ga-PSMA-11 PET quantitative volumetric tumor parameters including whole-body total-lesion PSMA (TL-PSMA), whole-body PSMA-tumor volume (PSMA-TV), as well as the established maximum standard uptake values (SUVmax) and mean standard uptake values (SUVmean), all 443
68
Ga-PSMA-11-positive bone lesions in the field of view were assessed quantitatively. Quantitative volumetric tumor parameters were correlated with CT-derived volume and bone density measurements of metastatic bone lesions, serum prostate-specific antigen (PSA) levels, and Gleason Scores. In the 20 patients suffering from bone metastases who underwent
68
Ga-PSMA-11 PET/CT before and after therapy, CT-derived volume and bone density measurements of metastatic lesions were compared to biochemical response determined by serum-PSA levels.
Results
In 177 patients, a total of 443
68
Ga-PSMA-11 PET-positive bone lesions were detected. Of these, 50 lesions (11%) were only detectable on PET but not on conventional CT. PET-positive/CT-negative bone metastases demonstrated a significantly lower PSMA uptake compared to PET-positive/CT-positive bone lesions (
p
< 0.05). SUVmax, SUVmean, PSMA-TV, and TL-PSMA of bone metastases were significantly higher (
p
< 0.05) in patients with Gleason Scores > 7 compared to those with Gleason Scores ≤ 7. In the linear regression analysis, an association was determined between SUVmean, Gleason Scores, lesion classification, and serum-PSA levels but not for CT-derived bone density measurements. No significant correlation could be found between changes of bone density and CT-derived volume measurements of metastatic bone lesions and changes of serum-PSA levels (
p
> 0.05) before and after therapy, while a highly significant correlation was observed for changes of PSMA-TV, TL-PSMA, and serum-PSA levels (
p
< 0.001).
Conclusion
Our results suggest that
68
Ga-PSMA-11 PET/CT might be a valuable tool for the detection and follow-up of bone metastases in patients with metastasized prostate cancer.
68
Ga-PSMA-11 PET-derived quantitative volumetric parameters demonstrated a highly significant correlation with changes of serum-PSA levels during the course of therapy. No such correlation could be determined for bone density measurements of metastatic bone lesions. Compared to the fully diagnostic CT scan, a significantly higher proportion of bone metastases was detected on
68
Ga-PSMA-11 PET.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>31338731</pmid><doi>10.1007/s12149-019-01387-0</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-1988-0058</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0914-7187 |
| ispartof | Annals of nuclear medicine, 2019-10, Vol.33 (10), p.766-775 |
| issn | 0914-7187 1864-6433 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2263323253 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Aged, 80 and over Antigens Bone cancer Bone density Bone lesions Bone Neoplasms - diagnostic imaging Bone Neoplasms - secondary Bone Neoplasms - therapy Classification Computed tomography Correlation analysis Diagnostic systems Edetic Acid - analogs & derivatives Emission analysis Evaluation Field of view Humans Imaging Lesions Male Medicine Medicine & Public Health Metastases Metastasis Middle Aged Neoplasm Grading Nuclear Medicine Oligopeptides Original Article Parameters Personal computers Positron emission Positron emission tomography Positron Emission Tomography Computed Tomography Prostate cancer Prostate-specific antigen Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology Radiology Recurrence Regression analysis Therapy Time Factors Tomography Treatment Outcome Tumors |
| title | 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T06%3A29%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=68Ga-PSMA-11%20PET/CT%20derived%20quantitative%20volumetric%20tumor%20parameters%20for%20classification%20and%20evaluation%20of%20therapeutic%20response%20of%20bone%20metastases%20in%20prostate%20cancer%20patients&rft.jtitle=Annals%20of%20nuclear%20medicine&rft.au=Schmidkonz,%20Christian&rft.date=2019-10-01&rft.volume=33&rft.issue=10&rft.spage=766&rft.epage=775&rft.pages=766-775&rft.issn=0914-7187&rft.eissn=1864-6433&rft_id=info:doi/10.1007/s12149-019-01387-0&rft_dat=%3Cproquest_cross%3E2263323253%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2299479034&rft_id=info:pmid/31338731&rfr_iscdi=true |